Pfizer Had Clues Its Blockbuster Drug Could Prevent Alzheimer’s. Why Didn’t It Tell the World? June 6, 2019 Robert I. Field, PhD, JD, a professor in the Dornsife School of Public Health and Kline School of Law, was quoted in a June 4 Washington Post article about a team of Pfizer researchers who found its rheumatoid arthritis therapy drug could also potentially reduce the risk of Alzheimer’s disease. Field explained the procedures a company must go through to receive regulatory approval to use a drug for a completely different disease. View story
icon above to turn off Compatibility Mode, which is only for viewing older websites.